Royal Bank of Canada
SRPT icon

Royal Bank of Canada’s Sarepta Therapeutics SRPT Stock Holding History

Royal Bank of Canada’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,800
Closed -$185K – 7508
2025
Q2 		$185K Sell
10,800
-127,000
-92% -$5.42M ﹤0.01% 5225
2025
Q1 		$8.79M Buy
+137,800
New +$14.5M ﹤0.01% 1843
2019
Q3 		– Sell
-100
Closed -$15K – 7080
2019
Q2 		$15K Buy
+100
New +$12.2K ﹤0.01% 5860

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's SRPT Position: Q1 2026 in Review

Royal Bank of Canada increased its Sarepta Therapeutics (SRPT) stake by 7.7% in Q1 2026, buying an estimated $308K and bringing the position to 222,850 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2440.

Royal Bank of Canada first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $78.5M in Q4 2023. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Royal Bank of Canada held 222,850 shares of Sarepta Therapeutics worth $4.85M as of Q1 2026.
  • Royal Bank of Canada bought 15,888 Sarepta Therapeutics shares in Q1 2026, an estimated $308K.
  • Sarepta Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2440 holding.
  • Royal Bank of Canada first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Sarepta Therapeutics position peaked at $78.5M in Q4 2023.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.